The Impact Of ABSORB II: Down The Slippery Slope

When it was approved earlier this year in July the Absorb (Abbott) bioresorbable stent provoked a fair amount of discussion about the “slippery slope of noninferiority.” Although the stent met the FDA criteria for approval, the available trial results went in the wrong direction and there was a particularly concerning warning sign of a higher…

Click here to continue reading…

Reality Check On The ‘Noninferior’ Abbott Bioresorbable Stent

–The slippery slope of noninferiority. Last week the big news in interventional cardiology was the approval of Abbott’s bioresorbable stent, Absorb. There’s no doubt that this represents a remarkable technical achievement, propping open a clogged artery and then gradually disappearing. There are all sorts of theoretical reasons why this might represent an important advance over traditional stents that…

Click here to continue reading…

Guest Post: Why Is The National Library Of Medicine Still Indexing Reviews In Cardiovascular Medicine?

The following guest post by Kevin Lomangino was originally published on HealthNewsReview.org. Lomangino is an independent medical journalist and editor who is currently Editor-in-Chief of Clinical Nutrition Insight, a monthly evidence-based newsletter which reviews the scientific literature on nutrition for physicians and dietitians. He tweets as@Klomangino. Why Is the National Library of Medicine Still Indexing Reviews in Cardiovascular…

Click here to continue reading…